Orgenesis Inc. Common Stock
ORGS
ORGS: Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.
moreShow ORGS Financials
Recent trades of ORGS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ORGS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods of transdifferentiation and methods of use thereof Apr. 04, 2023
-
Patent Title: Prophylactic protection against viral infections May. 17, 2022
-
Patent Title: Transdifferentiated cell populations and methods of use thereof Apr. 13, 2021
-
Patent Title: Cell populations, methods of transdifferentiation and methods of use thereof Mar. 16, 2021
-
Patent Title: Prophylactic protection against viral infections, particularly hiv Nov. 17, 2020
-
Patent Title: Methods of transdifferentiation and methods of use thereof Jun. 02, 2020
-
Patent Title: Methods of transdifferentiation and methods of use thereof Jan. 15, 2019
-
Patent Title: Cell populations, methods of transdifferentiation and methods of use thereof May. 29, 2018
Federal grants, loans, and purchases
Followers on ORGS's company Twitter account
Number of mentions of ORGS in WallStreetBets Daily Discussion
Recent insights relating to ORGS
Recent picks made for ORGS stock on CNBC
ETFs with the largest estimated holdings in ORGS
Flights by private jets registered to ORGS